Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: A randomised placebo-controlled cross-over trial

International Journal of Cardiology

Volumn 168, Issue 6, 2013, Pages 5229-5233

  Wong, K Y K ^a,b   Wong, S Y S ^a   McSwiggan, S ^a   Ogston, S A ^a   Sze, K Y S ^b   Macwalter, R S ^a   Struthers, A D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Amiloride; Myocardial fibrosis; QTc; Spironolactone; Stroke

Indexed keywords

AMILORIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; PLACEBO; POTASSIUM; PROCOLLAGEN; PROCOLLAGEN 1 CARBOXY TERMINAL PEPTIDE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOWN REGULATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE PATIENT; SURVIVOR; TREATMENT DURATION;

AMILORIDE; MYOCARDIAL FIBROSIS; QTC; SPIRONOLACTONE; STROKE;

AGED; AMILORIDE; CROSS-OVER STUDIES; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; FIBROSIS; HEART DISEASES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LONG QT SYNDROME; MALE; PLACEBOS; POTASSIUM; PROCOLLAGEN; SPIRONOLACTONE; STROKE; SURVIVORS; TREATMENT OUTCOME;

EID: 84887153040     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.027     Document Type: Article

References (18)

1. M.S. Dennis, J.P. Burn, P.A. Sandercock, J.M. Bamford, D.T. Wade, and C.P. Warlow Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project Stroke 24 1993 796 800
2. K.Y.K. Wong, R.S. MacWalter, D. Douglas, H.W. Fraser, S.A. Ogston, and A.D. Struthers Long QTc predicts future cardiac death in stroke survivors Heart 89 2003 377 381
3. K.Y. Wong, S. McSwiggan, and N.S. Kennedy Spectrum of cardiac abnormalities associated with long QT in stroke survivors Heart 91 2005 1306 1310
4. B.N. Singh, N.K. Hollenberg, P.A. Poole-Wilson, and J.I. Robertson Diuretic-induced potassium and magnesium deficiency: relation to drug-induced QT prolongation, cardiac arrhythmias and sudden death J Hypertens 10 1992 301 316
5. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
6. C.A.J. Farquharson, and A.D. Struthers Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure Heart 88 2002 475 480
7. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
8. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041 [Erratum in: Lancet 2001;358:1556. Lancet 2002;359:2120]
9. D.J. Sahn, A. DeMaria, J. Kisslo, and A. Weyman Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements Circulation 58 1978 1072 1083
10. P. Jepsen, S.P. Johnsen, M.W. Gillman, and H.T. Sørensen Interpretation of observational studies Heart 90 2004 956 960
11. S.J. Compton, R.L. Lux, and M.R. Ramsey Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium Circulation 94 1996 1018 1022
12. A.M. Choy, C.C. Lang, D.M. Chomsky, G.H. Rayos, J.R. Wilson, and D.M. Roden Normalization of acquired QT prolongation in humans by intravenous potassium Circulation 96 1997 2149 2154
13. O.M. Hess, J. Schneider, R. Koch, C. Bamert, J. Grimm, and H.P. Krayenbuehl Diastolic function and myocardial structure in patients with myocardial hypertrophy. Special reference to normalized viscoelastic data Circulation 63 1981 360 371
14. J.M. McLenachan, and H.J. Dargie Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis Am J Hypertens 3 1990 735 740
15. K.M. Yee, S.D. Pringle, and A.D. Struthers Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure J Am Coll Cardiol 37 2001 1800 1807
16. G. Klappacher, P. Franzen, and D. Haab Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis Am J Cardiol 75 1995 913 918
17. C.Y. Ho, B. López, and R.C. Filho Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy N Engl J Med 363 2010 552 563
18. N. Sherwi, S. Merali, and K. Wong Personalizing biomarker strategies in heart failure with galectin-3 Future Cardiol 8 6 2012 885 894